Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
Status:
Withdrawn
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to improve and personalize pancreatic cancer care to
deliver the most effective therapy while avoiding unnecessary exposure to potential side
effects. Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression
predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are
much more likely to respond to cisplatin than those whose tumors produce large amounts. The
hypothesis is that the combination of gemcitabine and oxaliplatin is a uniquely effective
regimen for patients with metastatic pancreatic cancer whose tumors have a low expression of
ERCC1.